The possibilities and results of the use of antioxidant therapy in ophthalmological practice

Authors:
A.B. MOVSISYAN^1,2, Zh.G. OGANEZOVA^2,3, E.A. EGOROV²

¹Hospital for War Veterans No. 2 of the Moscow Health Department, Moscow, Russia;
²Pirogov Russian National Research Medical University, Moscow, Russia;
³Bochkov Medical Genetic Research Center, Moscow, Russia

Place of publication:
VESTNIK OPHTHALMOLOGII, 5, 2022

Abstract:
The development of diagnostic technologies in medicine, particularly in ophthalmology, has made it possible to study the human eye not only at the histological level but also at the cellular level. The role of the nervous system in the functioning of the visual analyzer is associated not only with motor, protective, and sensory functions, but primarily with the visual process itself. Neurodegenerative diseases occupy a special place among systemic pathologies. Currently, the development of this process is associated with neuroinflammation, the role of which has been confirmed in glaucoma. For this reason, achieving target intraocular pressure does not always guarantee stabilization of the degenerative process. Therefore, neuroprotective medications are recommended for any patient with glaucoma, taking into account the specific pathogenesis of the disease. Due to its antioxidant and neuroprotective properties, ethylmethylhydroxypyridine succinate (Mexidol) is widely used in ophthalmology, particularly in the treatment of patients with glaucomatous optic neuropathy and retinal diseases. Study results demonstrated Mexidol's effectiveness in slowing neurodegeneration and stabilizing visual function in patients with primary open-angle glaucoma due to its antihypoxic, antioxidant, and membrane-stabilizing properties, as well as its positive impact on neurotransmitter balance and ocular blood flow. Key words: ophthalmology, eye, neuroinflammation, glaucoma, glaucomatous optic neuropathy, neuroprotection in glaucoma, ethylmethylhydroxypyridine succinate, Mexidol, Mexidol FORTE 250.